IASLC/WCLC 2019

Complete Coverage

Pembrolizumab Shows Overall Survival Benefit at 3 Years in Advanced NSCLC

By

Christina Bennett, MS

Publish Date September 11, 2019

KEYNOTE-024 shows first-line pembrolizumab has long-term overall survival benefit in patients with advanced non-small cell lung cancer and PD-L1–expressing disease.

Long-Term OS Benefit for Nivolumab Vs Docetaxel in Previously Treated Patients With Advanced NSCLC: A Pooled Analysis

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.

Rationale for Mesothelin-Directed CAR-T Therapy in Metastatic, KRAS-Mutant Lung Adenocarcinoma

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

Preclinical studies performed in cell line and mouse models of lung adenocarcinoma showed that mesothelin-directed CAR-T was effective and not associated with toxicity.

No OS Benefit for Addition of Atezolizumab to Nab-Paclitaxel and Carboplatin in Squamous NSCLC Unselected for Tumor PD-L1 Expression

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

OS was significantly higher in the subgroup of patients with high tumor expression of PD-L1 who received atezolizumab plus chemotherapy compared with chemotherapy alone.

Immunotherapy-Induced Hyperprogressive Disease Is Real

By

Randi Hernandez

Publish Date September 10, 2019

Disease progression was accelerated in nearly 21% of NSCLC patients who received immunotherapy during the trial, suggesting this treatment may be detrimental for some.

OS Benefit Seen With Addition of Durvalumab to Standard Chemotherapy in Extensive-Stage SCLC

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

The incidences of grade 3/4 AEs were high but similar in both study arms, although the rate of hematologic AEs was higher in the chemotherapy alone arm.

Quality of Life Is Underreported Across Phase 3 Lung Cancer Trials

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

QoL measures either remained unpublished — despite being studied — or were not reported at all.

Insights From the Largest Global Precision Medicine Trial in NSCLC: The National Lung Matrix Trial

By

Susan Moench, PhD, PA-C

Publish Date September 10, 2019

Continued molecular stratification in lung cancer appears imminent, and many of the patients in these genetic subgroups may benefit from the use of targeted therapies.

Promising Efficacy and Safety for Selpercatinib, a RET Fusion Inhibitor, in Advanced NSCLC

By

Susan Moench, PhD, PA-C

Publish Date September 9, 2019

Fewer than 2% of the people in the LIBRETTO-001 study discontinued treatment with selpercatinib due to treatment-related adverse events.

Early Evidence Supporting KRAS G12C as a Druggable Target: High Response Rate for AMG 510 in Advanced NSCLC

By

Susan Moench, PhD, PA-C

Publish Date September 9, 2019

Of the 23 patients with NSCLC who were evaluable for efficacy, the overall response rate was 48%, with a disease control rate of 96%.

Meta-Analysis Shows No OS Benefit of Prophylactic Cranial Irradiation in Patients With Localized NSCLC

By

Susan Moench, PhD, PA-C

Publish Date September 6, 2019

Prophylactic cranial irradiation was determined to be tolerable; few adverse effects were observed in patients with stage III NSCLC receiving this treatment.

Patients With Metastatic NSCLC Characterized by LKB1 Mutations Found Less Likely to Benefit From First-Line Chemotherapy

By

Susan Moench, PhD, PA-C

Publish Date September 6, 2019

In this study, LKB1 mutations without coexisting KRAS mutations were found in the tumor specimens of 13.6% of patients with metastatic NSCLC.